| Metric | Value ($ M) | Q2 FY26 | Q3 FY25 |
|---|---|---|---|
| Revenue | 357.81 | 0.8% | 69.6% |
| Total Income | 357.81 | 0.8% | 69.6% |
| Expenditure | 332.69 | 57.3% | 60.0% |
| PBT | -41.09 | 142.1% | 78.1% |
| Net Profit | -51.69 | 161.9% | 425.1% |
| OPM | 7.02% | 34.30pp | 5.59pp |
| NPM | -14.45% | 37.61pp | 21.98pp |
| EPS | -0.62 | 161.4% | 410.0% |
PTC Therapeutics Reports Q3 2026 Financial Results and Provides Corporate Update
30 Oct 2026 · 30 Oct, 1:45 am
Summary
PTC Therapeutics announced its third quarter 2026 financial results, reporting total revenue of $358 million, with product revenue reaching $276 million. The company raised its full-year 2026 revenue guidance to $1.29-$1.32 billion, including an increased product revenue forecast of $960-$990 million. Despite a net loss of $51.7 million for the quarter, driven partly by the acquisition of the ST-920 gene therapy, the company highlighted strong momentum from Sephience and progress across its pipeline, including an expected BLA submission for ST-920 in Q4 2026.
Key Highlights
- 1
PTC Therapeutics reported total revenue of $358 million for the third quarter of 2026, including $276 million in product revenue.
- 2
Sephience™ generated $182 million in revenue in Q3 2026, showing continued growth in the US and international markets.
- 3
Full-year 2026 total revenue guidance was increased to a range of $1.29 to $1.32 billion, with product revenue guidance raised to $960 to $990 million.
- 4
The company expects to complete the Biologics License Application (BLA) submission for the ST-920 Fabry disease gene therapy in Q4 2026.
- 5
Net loss for the third quarter of 2026 was $51.7 million, compared to a net income of $15.9 million in the third quarter of 2025.
- 6
Cash, cash equivalents, and marketable securities stood at $2,127.9 million as of September 30, 2026.
Management Comments
Matthew B. Klein
We delivered another strong quarter of record product revenue led by the continued momentum of the Sephience launch, putting us firmly on track to achieve our cash flow breakeven milestone this year. Now at the one-year mark, the launch has been a success by all measures. With a strong patient base, the large global market, and the reports of meaningful treatment benefits, we look forward to continued growth both in the US and internationally.
Informational and educational content only. Not investment advice.